Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336943 · ClinicalTrials.gov registry record · Phase 2
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04336943 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 6 participants.
The verdict
NCT04336943, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial studies how well durvalumab and olaparib work in treating prostate cancer in men predicted to have specific genetic mutations (a high neoantigen load). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Giving durvalumab and olaparib may kill more tumor cells in patients with prostate cancer predicted to have a high neoantigen load.
Interventions
- OTHER Quality-of-Life Assessment
- BIOLOGICAL Durvalumab
- DRUG Olaparib
- OTHER Questionnaire Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2025-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04336943
The ClinicalTrials.gov registry entry for NCT04336943 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04336943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04336943 about?
NCT04336943 is a clinical study titled "Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load". This phase II trial studies how well durvalumab and olaparib work in treating prostate cancer in men predicted to have specific genetic mutations (a high neoantigen load). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may inter...
What is the current status of trial NCT04336943?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-04-13. Estimated completion is 2025-06-06.
What interventions are being tested in trial NCT04336943?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Durvalumab (BIOLOGICAL), Olaparib (DRUG), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT04336943?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.